Business, Cancer Research

Eric Lefkofsky is a professional businessman and philanthropist who co-founded a company by the name of Tempus. He is also currently the CEO of Tempus that focuses on creating advanced technology that has built an operating system to help battle cancer. He is also a partner and founder of an investing company called Lightbank. Lightbank is a venture fund that focuses its efforts investing in disruptive technologies. Aside from all of his business ventures, he also has a hand as the Chairman and co-founder of Groupon. Groupon is a global e-commerce marketplace that offers thousands of discounted deals. He started Uptake Technologies which is a predictive analytics platform in relation to the world’s largest industries like Mediaocean, Echo Global Logistics and InnerWorkings. He has been involved in many start up businesses along with many successful endeavors and continues to build his companies to a successful status.

Eric Lefkofsky has also been involved in many foundations and organizations. He started the Lefkofsky Family Foundation in 2006 with his wife, Liz. The private foundation focuses on advanced high-impact movements that are made to enhance the lives within each community. Together they have had the opportunity to enhance the quality within the lives of people all over the world. Lefkofsky also serves as a Trustee of Luri Children’s Hospital in Chicago. He takes a positive and avid approach to the business of the hospital and is dedicated to the overall growth and structure of the business. He also is part of The Art Institute of Chicago and The Museum of Science along with the World Business Chicago. Lefkofsky is also involved in the Steppenwolf Theatre Company where he serves as the Chairman of the Board of Trustees. Aside from his philanthrhopic businesses and ventures, he works as a professor at the University of Chicago. He is also the author of a book called Accelerated Disruption. He received his education from the University of Michigan where he obtained his bachelor’s degree. He went on to achieve his Juris Doctor degree from the University of Michigan Law School. His years of experience in a wide variety of industries has painted Lefkofsky as a very successful businessman and contact him.

More visit: http://www.lightbank.com/team/eric-lefkofsky

Cancer Research, Oncotarget

Oncotarget is the first of its kind in medicine. It is one of the first times that there has been a peer review publication that has allowed people the chance to learn about cancer that they are able to do in medicine based on things that other doctors have done. While peer review publications are not uncommon in medicine, they are usually based in a singular practice and they are able to help people who are in that practice only. It is a discipline that has made things harder for people to try and get the best experience and it is something that has made it difficult for medical professionals to learn as much as they can. Since the beginning of medicine, many specialists have been divided and have been isolated to their own type of practice because of the issues that come with trying to make all of this work.

Despite the fact that there are no other publications even similar to it, Oncotarget has not seen too many issues in the past. In fact, the publication has done better than most. While Mikhail Blagosklonny has backed it up because he was the one who came up with the idea for treat cancer, there are also many other oncologists who are interested in what they can do to make sure that they are helping their patients. They have learned different things about medicine and what different things they can do to make sure that they are able to konw how to  treat cancer.

For people who have fought cancer, it is easy to see how poorly the immune system is able to perform. About Mikhail Blagosklonny he knew this and knew that he was going to find an answer in Oncotarget. What he didn’t know was that it would be able to come from a cosmetic surgery practice. This was something that he was surprised at and something that he tried to make work for his patients. By using cell rejuvenation techniques, Mikhail Blagosklonny made it possible to help people who had suppressed immune systems from cancer and it was all a result of Oncotarget.

Business, Cancer Research

Experts say that at some point in their lives, 40 percent of adults in the U.S. will be diagnosed with cancer. The National Cancer Institute estimates that by 2024 there will be over 19 million people in the country with cancer. Tempus, co-founded by Eric Lekofsky, is helping stem that tide by leading the development of data-enabled precision medicine. Lekofsky, the co-founder of Groupon, quickly grew a strong desire to find effective cancer treatment after his wife was diagnosed with breast cancer.

After intensive research, he found that one of the biggest deficiencies in the area of cancer treatment was in data collection and digital technology. With the goal of filling this gap, he helped start Tempus. They immediately went about developing a method to analyze each cancer patients clinical and molecular data to thereby form a precise course of treatment. The fledgling company overcame the early problem of providing accessible and affordable clinical and medical data.

Tempus developed software that makes it easy for doctors to look up the precise details of the cancer patient in their care. All of the available information is constantly updated as the information comes in. In addition, although the technological data of individual patients had technically been around for some time, Tempus made it exceedingly less expense. We are talking about a drop from $100 million to just $5,000. This process, called human genome sequencing, is expected to drop even further in the coming years and more information click here.

Human gene study is widely viewed as being the key to effectively fight cancer so this is where Tempus will stay. Lefkofsky fully anticipates that Tempus will uncover many more cancer-combating secrets in the coming years. But as time goes on Tempus will undoubtedly have more and more competition as more organizations are starting up to do the same thing and learn more about Eric.

More Visit: http://www.lightbank.com/team/eric-lefkofsky

Business Ventures, Cancer Research

Today, effective cancer treatments seem a little too elusive. Part of the reason why this is the case is due to the fact there is insufficient therapeutic data on cancer patients. One of the people who discovered this is billionaire Eric Lefkofsky. When his wife was diagnosed with breast cancer, he was amazed by the size of data that was available for oncologists. The data was too little to draw any meaningful patterns that could help design and administer more effective therapies to patients.

At this year’s Fortune Brainstorm Health Conference that took place in San Diego, Eric Lefkofsky noted that advancements in the treatment of cancer such CRISPR and personalized vaccines require significant data from cancer patients who have battled the different types of cancer. One of Eric’s main objectives is to come up with a data warehouse that could aggregate genomic sequencing data vis-à-vis therapeutic or clinical data of cancer patients. This objective informed his recent creation, Tempus. Tempus is a data aggregation and analytics company that is focused on collecting data from cancer patients and availing it to medical gurus who will use the data to draw meaningful patterns that could inform the design of future therapies.

Currently, it’s quite a daunting task to get therapeutic data of cancer patients under various treatments. You would need special permissions and a window period of up to 90 days before you can get this crucial data. Tempus is keen on changing this trend by leveraging technology to aggregate data that will be critical to oncologists and Eric’s lacrosse camp.

Eric Lefkofsky stands as one of the few billionaires who are devoted to pioneer solutions to challenges facing medical professionals while they administer treatments to clients. Tempus is not the only successful venture that is linked to Eric Lefkofsky. Lefkofsky is the entrepreneur behind retail giant Groupon and many others. It is evident that Eric is one of the few social entrepreneurs in the world. Lightbank is a venture capital enterprise that Eric built together with his all-time business partner Brad Keywell. The firm has made important investments in various sectors of the economy and more information click here.

Other Reference: www.forbes.com/profile/eric-lefkofsky

Cancer Research, New Software

Eric Lefkofsky is an American serial investor and a philanthropist. He is the co-founder and CEO of Tempus, which is a technology company focused on fighting cancer. Additionally, he serves as a professor at the University of Chicago and the author of Accelerated Disruption. Eric Lefkofsky (http://www.bizjournals.com/chicago/news/2016/10/04/groupons-eric-lefkofsky-returns-to-the-forbes-400.html) studied at the University of Michigan and acquired his Juris Doctor from University of Michigan Law School. Lefkofsky began his career in business by selling carpets while still at the university.

 

 

Career Background

 

 

After graduating, he teamed up with Bradley Keywell in the purchase of Brendon Apparel in 1994. They co-founded Starbelly in 1999 and sold it for $240 million. Eric Lefkofsky has served in executive positions to the companies that he has founded and co-founded. He co-founded Lightbank and worked as the Managing Director of the company. Lightbank is a venture fund that specializes in disruptive technology businesses. He was the founder and the CEO of InnerWorkings, a global print management, and brand delivery company in Chicago. Lefkofsky launched Echo Global Logistics in 2005.

 

 

Erick founded MediaBank in 2006 where he works to date. Eric Lefkofsky is the co-founder and Chairman of Groupon. Groupon is a local commerce company with its headquarters in Chicago. Before starting Tempus, Eric cofounded Uptake in 2014, is a predictive analytics company. Eric Lefkofsky donated millions of dollars in support of cancer research. His interests in finding treatment for cancer led to the launch of Tempus in 2015.

 

 

Tempus Inc.

 

 

Tempus Inc. is a Chicago-based startup that specializes in building infrastructure for cancer treatment. The company has highly qualified professionals who use statistical analysis and algorithms to collect and analyze genomic data. The data collected helps the physicians in prescribing more precise and personalized medicine to the cancer patients. Currently, the company works with the breast, lung, pancreatic and lung cancer patients.

 

 

Philanthropy

 

 

Eric Lefkofsky and his wife Liz founded Lefkofsky Family Foundation in 2006. The private charitable foundation focuses on improving the quality of human life through high impact programs, initiative, and research. The foundation has its interests in various sectors such as education, health care, human rights, arts, culture, and medical research. They have supported various health causes in both Chicago and U.S at large. The foundation donates mainly to the medical centers that support treatment of children and different types of cancers such as leukemia, lung, thyroid, and pancreatic cancer.

 

 

Lefkofsky Family Foundation also pioneered Moneythink, which provides mentorship and financial lessons to urban schools. Additionally, the organizations also donated $1.2 million to the University of Michigan Health System. Lefkofsky is a great supporter of the arts and culture industry in Chicago. He has generously contributed to the Chicago Museum of Contemporary Arts, The Art Institute of Chicago, and Steppenwolf Theatre Company.

Twitter: @lefkofksy